The health care industry's biggest conference just finished up, and the Fool's health care team was keeping close watch. While much of the interest was focused on biotech outfits big and small, the industry's titans -- the big pharmaceutical companies -- made some noise of their own.
Our health care bureau chief Brenton Flynn paid close attention to what they had to say, particularly in terms of M&A plans, but hasn't changed his position on the elephant in the room -- the speculation around a big pharma Bausch & Lomb buyout.
What's inside Supernova?
Big pharma stocks are a great defensive play, but if you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.